Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 436

1.

Re: Screening and Prostate Cancer Mortality: Results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 Years of Follow-up.

Taneja SS.

J Urol. 2015 Aug;194(2):392-4. doi: 10.1016/j.juro.2015.05.064. Epub 2015 May 18. No abstract available.

PMID:
26195362
2.

Corrigendum to "Incidence of Prostate Cancer After Termination of Screening in a Population-based Randomised Screening Trial" [Eur Urol 2013;64:703-9].

Bergdahl AG, Holmberg E, Moss S, Hugosson J.

Eur Urol. 2015 Aug;68(2):e46. doi: 10.1016/j.eururo.2015.01.021. Epub 2015 Feb 4. No abstract available.

PMID:
26149731
3.

A pilot randomised controlled trial of personalised care after treatment for prostate cancer (TOPCAT-P): nurse-led holistic-needs assessment and individualised psychoeducational intervention: study protocol.

Stanciu MA, Morris C, Makin M, Watson E, Bulger J, Evans R, Hiscock J, Hoare Z, Edwards RT, Neal RD, Wilkinson C.

BMJ Open. 2015 Jun 25;5(6):e008470. doi: 10.1136/bmjopen-2015-008470.

4.

Prostate cancer.

Attard G, Parker C, Eeles RA, Schröder F, Tomlins SA, Tannock I, Drake CG, de Bono JS.

Lancet. 2015 Jun 11. pii: S0140-6736(14)61947-4. doi: 10.1016/S0140-6736(14)61947-4. [Epub ahead of print] Review.

PMID:
26074382
5.

Survivorship and Improving Quality of Life in Men with Prostate Cancer.

Bourke L, Boorjian SA, Briganti A, Klotz L, Mucci L, Resnick MJ, Rosario DJ, Skolarus TA, Penson DF.

Eur Urol. 2015 May 1. pii: S0302-2838(15)00325-5. doi: 10.1016/j.eururo.2015.04.023. [Epub ahead of print] Review.

PMID:
25941049
6.

Impact of a printed decision aid on patients' intention to undergo prostate cancer screening: a multicentre, pragmatic randomised controlled trial in primary care.

Tran VT, Kisseleva-Romanova E, Rigal L, Falcoff H.

Br J Gen Pract. 2015 May;65(634):e295-304. doi: 10.3399/bjgp15X684817.

PMID:
25918334
7.

Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial.

Loriot Y, Miller K, Sternberg CN, Fizazi K, De Bono JS, Chowdhury S, Higano CS, Noonberg S, Holmstrom S, Mansbach H, Perabo FG, Phung D, Ivanescu C, Skaltsa K, Beer TM, Tombal B.

Lancet Oncol. 2015 May;16(5):509-21. doi: 10.1016/S1470-2045(15)70113-0. Epub 2015 Apr 14.

PMID:
25888263
8.

Assessing the effectiveness of decision aids for decision making in prostate cancer testing: a systematic review.

Ilic D, Jammal W, Chiarelli P, Gardiner RA, Hughes S, Stefanovic D, Chambers SK.

Psychooncology. 2015 Apr 15. doi: 10.1002/pon.3815. [Epub ahead of print]

PMID:
25873433
9.

[Early detection of prostate cancer--recommendations after 13 years of follow-up in the European randomised study].

Schröder FH, Roobol MJ, Bangma CH.

Ned Tijdschr Geneeskd. 2015;159:A8677. Dutch.

PMID:
25850455
10.

[Development of patient education materials for the "German Prostate Cancer Trial PREFERE"].

Sänger S, Wiegel T, Stöckle M, Härter M, Bergelt C.

Z Evid Fortbild Qual Gesundhwes. 2015;109(1):28-39. doi: 10.1016/j.zefq.2015.01.014. Epub 2015 Mar 4. German.

PMID:
25839363
11.

Reiki for depression and anxiety.

Joyce J, Herbison GP.

Cochrane Database Syst Rev. 2015 Apr 3;4:CD006833. doi: 10.1002/14651858.CD006833.pub2.

PMID:
25835541
12.
13.

Physical activity, alcohol consumption, BMI and smoking status before and after prostate cancer diagnosis in the ProtecT trial: Opportunities for lifestyle modification.

Hackshaw-McGeagh LE, Penfold CM, Walsh E, Donovan JL, Hamdy FC, Neal DE, Jeffreys M, Martin RM, Lane JA; ProtecT Study Group.

Int J Cancer. 2015 Sep;137(6):1509-15. doi: 10.1002/ijc.29514. Epub 2015 Apr 1.

PMID:
25761662
14.

Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.

Petrylak DP, Vogelzang NJ, Budnik N, Wiechno PJ, Sternberg CN, Doner K, Bellmunt J, Burke JM, de Olza MO, Choudhury A, Gschwend JE, Kopyltsov E, Flechon A, Van As N, Houede N, Barton D, Fandi A, Jungnelius U, Li S, de Wit R, Fizazi K.

Lancet Oncol. 2015 Apr;16(4):417-25. doi: 10.1016/S1470-2045(15)70025-2. Epub 2015 Mar 3.

PMID:
25743937
15.

High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.

Zapatero A, Guerrero A, Maldonado X, Alvarez A, Gonzalez San Segundo C, Cabeza Rodríguez MA, Macias V, Pedro Olive A, Casas F, Boladeras A, de Vidales CM, Vazquez de la Torre ML, Villà S, Perez de la Haza A, Calvo FA.

Lancet Oncol. 2015 Mar;16(3):320-7. doi: 10.1016/S1470-2045(15)70045-8. Epub 2015 Feb 19.

PMID:
25702876
16.

Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial.

Saad F, Fizazi K, Jinga V, Efstathiou E, Fong PC, Hart LL, Jones R, McDermott R, Wirth M, Suzuki K, MacLean DB, Wang L, Akaza H, Nelson J, Scher HI, Dreicer R, Webb IJ, de Wit R; ELM-PC 4 investigators.

Lancet Oncol. 2015 Mar;16(3):338-48. doi: 10.1016/S1470-2045(15)70027-6. Epub 2015 Feb 18.

PMID:
25701170
17.

[Adjuvant vs. salvage radiotherapy after radical prostatectomy].

Bartkowiak D, Schrader AJ, Wiegel T.

Aktuelle Urol. 2015 Jan;46(1):52-8. doi: 10.1055/s-0034-1395656. Epub 2015 Feb 6. German.

PMID:
25658231
18.

Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.

Aluwini S, Pos F, Schimmel E, van Lin E, Krol S, van der Toorn PP, de Jager H, Dirkx M, Alemayehu WG, Heijmen B, Incrocci L.

Lancet Oncol. 2015 Mar;16(3):274-83. doi: 10.1016/S1470-2045(14)70482-6. Epub 2015 Feb 3. Erratum in: Lancet Oncol. 2015 Mar;16(3):e105.

PMID:
25656287
19.

Standardisation of information submitted to an endpoint committee for cause of death assignment in a cancer screening trial – lessons learnt from CAP (Cluster randomised triAl of PSA testing for Prostate cancer).

Williams NJ, Hill EM, Ng SY, Martin RM, Metcalfe C, Donovan JL, Evans S, Hughes LJ, Davies CF, Hamdy FC, Neal DE, Turner EL; CAP Cause of Death Committee.

BMC Med Res Methodol. 2015 Jan 23;15:6. doi: 10.1186/1471-2288-15-6.

20.

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.

Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE; COU-AA-302 Investigators.

Lancet Oncol. 2015 Feb;16(2):152-60. doi: 10.1016/S1470-2045(14)71205-7. Epub 2015 Jan 16.

PMID:
25601341
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk